Molecular characterization of a thyroid tumor-specific transforming sequence formed by the fusion of ret tyrosine kinase and the regulatory subunit RI alpha of cyclic AMP-dependent protein kinase A
- PMID: 7678053
- PMCID: PMC358915
- DOI: 10.1128/mcb.13.1.358-366.1993
Molecular characterization of a thyroid tumor-specific transforming sequence formed by the fusion of ret tyrosine kinase and the regulatory subunit RI alpha of cyclic AMP-dependent protein kinase A
Abstract
The ret oncogene frequently has been found activated in papillary thyroid carcinomas. A previous characterization of ret activation revealed recombination of its tyrosine kinase domain and sequences derived from an uncharacterized locus (D10S170). The mechanism leading to this recombination was identified as a paracentric inversion of the long arm of chromosome 10, inv(10)(q11.2q21), with the breakpoints occurring where ret and D10S170 were mapped. To further characterize the activation of ret in papillary thyroid carcinomas, we have now isolated and sequenced a second type of ret oncogenic rearrangement not involving the D10S170 locus. The nucleotide sequence indicated that the transforming activity was created by the fusion of the ret tyrosine kinase domain with part of the RI alpha regulatory subunit of protein kinase A (PKA). This is the first example of an oncogenic activity involving a PKA gene. PKA is the main intracellular cyclic AMP receptor, and its RI alpha subunit gene is located on chromosome 17q. RI alpha-ret transcripts encode two isoforms of the chimeric protein (p76 and p81), which display constitutive tyrosine phosphorylation as well as a tyrosine kinase enzymatic activity. Under nonreducing conditions, both isoforms are found in a dimeric configuration because of both homo- and heterodimer formation. Thus, the in vivo activation of ret in human papillary thyroid carcinomas is provided by the fusion of its tyrosine kinase domain with different genes and can be mediated by different mechanisms of gene rearrangement.
Similar articles
-
Frequent activation of ret protooncogene by fusion with a new activating gene in papillary thyroid carcinomas.Cancer Res. 1994 Jun 1;54(11):2979-85. Cancer Res. 1994. PMID: 8187085
-
Characterization of an inversion on the long arm of chromosome 10 juxtaposing D10S170 and RET and creating the oncogenic sequence RET/PTC.Proc Natl Acad Sci U S A. 1992 Mar 1;89(5):1616-20. doi: 10.1073/pnas.89.5.1616. Proc Natl Acad Sci U S A. 1992. PMID: 1542652 Free PMC article.
-
A t(10;17) translocation creates the RET/PTC2 chimeric transforming sequence in papillary thyroid carcinoma.Genes Chromosomes Cancer. 1994 Apr;9(4):244-50. doi: 10.1002/gcc.2870090404. Genes Chromosomes Cancer. 1994. PMID: 7519046
-
Molecular genetics of childhood papillary thyroid carcinomas after irradiation: high prevalence of RET rearrangement.Recent Results Cancer Res. 1998;154:248-64. doi: 10.1007/978-3-642-46870-4_16. Recent Results Cancer Res. 1998. PMID: 10027005 Review.
-
[Rearrangement of the RET gene in papillary thyroid carcinoma].Wiad Lek. 2001;54 Suppl 1:64-71. Wiad Lek. 2001. PMID: 12182064 Review. Polish.
Cited by
-
Selpercatinib combination with the mitochondria-targeted antioxidant MitoQ effectively suppresses RET-mutant thyroid cancer.NPJ Precis Oncol. 2024 Feb 20;8(1):39. doi: 10.1038/s41698-024-00536-7. NPJ Precis Oncol. 2024. PMID: 38378752 Free PMC article.
-
RET fusion genes in pediatric and adult thyroid carcinomas: cohort characteristics and prognosis.Endocr Relat Cancer. 2023 Oct 26;30(12):e230117. doi: 10.1530/ERC-23-0117. Print 2023 Dec 1. Endocr Relat Cancer. 2023. PMID: 37882481 Free PMC article.
-
RET signaling pathway and RET inhibitors in human cancer.Front Oncol. 2022 Jul 25;12:932353. doi: 10.3389/fonc.2022.932353. eCollection 2022. Front Oncol. 2022. PMID: 35957881 Free PMC article. Review.
-
RET kinase inhibitors for RET-altered thyroid cancers.Ther Adv Med Oncol. 2022 Jun 21;14:17588359221101691. doi: 10.1177/17588359221101691. eCollection 2022. Ther Adv Med Oncol. 2022. PMID: 35756966 Free PMC article. Review.
-
The Genomic Landscape of Thyroid Cancer Tumourigenesis and Implications for Immunotherapy.Cells. 2021 May 1;10(5):1082. doi: 10.3390/cells10051082. Cells. 2021. PMID: 34062862 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
Associated data
- Actions
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Molecular Biology Databases
